387 related articles for article (PubMed ID: 31075742)
1. Selective cyclooxygenase inhibition and ulcerogenic liability of some newly prepared anti-inflammatory agents having thiazolo[4,5-d]pyrimidine scaffold.
Bakr RB; Ghoneim AA; Azouz AA
Bioorg Chem; 2019 Jul; 88():102964. PubMed ID: 31075742
[TBL] [Abstract][Full Text] [Related]
2. Novel pyrimidine-pyridine hybrids: Synthesis, cyclooxygenase inhibition, anti-inflammatory activity and ulcerogenic liability.
Abdelgawad MA; Bakr RB; Azouz AA
Bioorg Chem; 2018 Apr; 77():339-348. PubMed ID: 29421710
[TBL] [Abstract][Full Text] [Related]
3. New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation.
Ahmed EM; Hassan MSA; El-Malah AA; Kassab AE
Bioorg Chem; 2020 Jan; 95():103497. PubMed ID: 31838289
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.
Ahmed EM; Kassab AE; El-Malah AA; Hassan MSA
Eur J Med Chem; 2019 Jun; 171():25-37. PubMed ID: 30904755
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies.
Alfayomy AM; Abdel-Aziz SA; Marzouk AA; Shaykoon MSA; Narumi A; Konno H; Abou-Seri SM; Ragab FAF
Bioorg Chem; 2021 Mar; 108():104555. PubMed ID: 33376011
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of 4-aminosalicylate with thiazolinones afforded non-cytotoxic potent in vitro and in vivo anti-inflammatory hybrids.
Abdu-Allah HHM; Abdelmoez AAB; Tarazi H; El-Shorbagi AA; El-Awady R
Bioorg Chem; 2020 Jan; 94():103378. PubMed ID: 31677858
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo[3,4-d]pyrimidine derivatives.
Bakr RB; Azouz AA; Abdellatif KR
J Enzyme Inhib Med Chem; 2016; 31(sup2):6-12. PubMed ID: 27210522
[TBL] [Abstract][Full Text] [Related]
8. New indomethacin analogs as selective COX-2 inhibitors: Synthesis, COX-1/2 inhibitory activity, anti-inflammatory, ulcerogenicity, histopathological, and docking studies.
Abdellatif KRA; Abdelall EKA; Elshemy HAH; El-Nahass ES; Abdel-Fattah MM; Abdelgawad YYM
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000328. PubMed ID: 33314237
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of new pyrazoles and pyrozolo [3,4-b] pyridines as anti-inflammatory agents by inhibition of COX-2 enzyme.
Mohamed LW; Shaaban MA; Zaher AF; Alhamaky SM; Elsahar AM
Bioorg Chem; 2019 Mar; 83():47-54. PubMed ID: 30342385
[TBL] [Abstract][Full Text] [Related]
10. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE
Labib MB; Fayez AM; El-Nahass ES; Awadallah M; Halim PA
Bioorg Chem; 2020 Nov; 104():104308. PubMed ID: 33011534
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study.
Abdellatif KRA; Abdelall EKA; Elshemy HAH; Philoppes JN; Hassanein EHM; Kahk NM
Bioorg Chem; 2022 Mar; 120():105627. PubMed ID: 35065465
[TBL] [Abstract][Full Text] [Related]
12. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2/5-LOX enzymes: Histopathological and docking studies.
Abdelgawad MA; Labib MB; Ali WAM; Kamel G; Azouz AA; El-Nahass ES
Bioorg Chem; 2018 Aug; 78():103-114. PubMed ID: 29550530
[TBL] [Abstract][Full Text] [Related]
14. Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors.
Murahari M; Mahajan V; Neeladri S; Kumar MS; Mayur YC
Bioorg Chem; 2019 May; 86():583-597. PubMed ID: 30782576
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.
Grover J; Kumar V; Sobhia ME; Jachak SM
Bioorg Med Chem Lett; 2014 Oct; 24(19):4638-4642. PubMed ID: 25219899
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,5-diarylpyrazole derivatives.
Abdellatif KR; Fadaly WA; Ali WA; Kamel GM
J Enzyme Inhib Med Chem; 2016; 31(sup3):54-60. PubMed ID: 27541738
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel halogenated triarylpyrazoles as selective COX-2 inhibitors: Anti-inflammatory activity, histopatholgical profile and in-silico studies.
Abdellatif KRA; Abdelall EKA; Labib MB; Fadaly WAA; Zidan TH
Bioorg Chem; 2020 Dec; 105():104418. PubMed ID: 33166844
[TBL] [Abstract][Full Text] [Related]
18. Novel tetrazole and cyanamide derivatives as inhibitors of cyclooxygenase-2 enzyme: design, synthesis, anti-inflammatory evaluation, ulcerogenic liability and docking study.
Lamie PF; Philoppes JN; Azouz AA; Safwat NM
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):805-820. PubMed ID: 28587532
[TBL] [Abstract][Full Text] [Related]
19. Novel sulindac derivatives: synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity.
Bhat MA; Al-Omar MA; Alsaif NA; Almehizia AA; Naglah AM; Razak S; Khan AA; Ashraf NM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):921-934. PubMed ID: 32238055
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation, and computational studies of novel thiazolo-pyrazole hybrids as promising selective COX-2 inhibitors: Implementation of apoptotic genes expression for ulcerogenic liability assessment.
Marzouk AA; Taher ES; Shaykoon MSA; Lan P; Abd-Allah WH; Aboregela AM; El-Behairy MF
Bioorg Chem; 2021 Jun; 111():104883. PubMed ID: 33865053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
